Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price upped by stock analysts at Truist Financial from $21.00 to $25.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has a "buy" rating on the stock. Truist Financial's price objective indicates a potential upside of 217.66% from the company's current price.
Several other equities analysts have also recently issued reports on the company. Piper Sandler boosted their target price on Sutro Biopharma from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 10th. HC Wainwright decreased their target price on shares of Sutro Biopharma from $30.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, November 9th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $19.67.
Get Sutro Biopharma alerts:Sutro Biopharma Stock Performance
Shares of Sutro Biopharma stock opened at $7.87 on Friday. The firm has a market capitalization of $452.29 million, a P/E ratio of -3.04 and a beta of 0.93. Sutro Biopharma has a 52 week low of $3.33 and a 52 week high of $10.98. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.03. The firm's 50 day moving average is $7.51 and its two-hundred day moving average is $6.52.
Sutro Biopharma (NASDAQ:STRO – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.22). The firm had revenue of $25.15 million during the quarter, compared to analysts' expectations of $11.35 million. Sutro Biopharma had a negative net margin of 175.85% and a negative return on equity of 53.85%. Research analysts forecast that Sutro Biopharma will post -2.59 EPS for the current fiscal year.Institutional Trading of Sutro Biopharma
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Quantbot Technologies LP purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth $37,000. Amalgamated Bank acquired a new stake in Sutro Biopharma in the 1st quarter worth about $44,000. Point72 Hong Kong Ltd purchased a new stake in Sutro Biopharma in the 2nd quarter valued at about $46,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth about $51,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Sutro Biopharma in the third quarter worth approximately $56,000. Hedge funds and other institutional investors own 87.64% of the company's stock.
Sutro Biopharma Company Profile
(Get Rating)
Sutro Biopharma Inc engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Recommended Stories
- Get a free copy of the StockNews.com research report on Sutro Biopharma (STRO)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.